Andrés Poveda

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.8K citations

Brca1/2 Mutation, Medicine, Cancer Management +10

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Éric Pujade-Lauraine, Felix Hilpert, B. Weber et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Amit M. Oza, Adrian Cook, Jacobus Pfisterer et al. · The Lancet Oncology · 2015 · 845 citations · Full text

Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)

Nicholas Reed, Costantino Mangioni, Henric Malmström et al. · European Journal of Cancer · 2008 · 520 citations

European Organisation, Radiation Therapy, Medicine +8

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

Bradley J. Monk, Thomas J. Herzog, Stanley B. Kaye et al. · Journal of Clinical Oncology · 2010 · 404 citations